New US patent covers fibroblast-based treatment for wounds that won’t close – increasingly common, and risky, with age.
Houston-based FibroBiologics got some good news from the patent office this month. The kind that matters a lot if you’re a company trying to build a business around cells that heal things other cells have given up on.
The US Patent and Trademark Office issued Patent No. 12,721,866 on 1 September titled “Therapeutic Use of Fibroblasts for Use in Wound Healing.” What it covers is a method for treating wounds, topically, with a composition built from fibroblasts, the cells that make collagen and hold connective tissue together, plus material those cells shed as they work [1].
Diabetic foot ulcers. Venous leg ulcers. Pressure sores. Burns. Even basic cuts and abrasions that, in the wrong patient, just won’t close. Those are the claims the patent covers, and it’s a wider net than you might expect for a single filing. In the preclinical studies described in the patent, wounds treated with the composition healed noticeably faster than untreated controls, and that pattern held in both diabetic and non-diabetic models, which is the harder test.
Here’s the part that’s interesting, though: what’s being applied isn’t a cream or a gel in the way people usually picture wound care. It’s fibroblast cells grown into small three-dimensional clusters, “spheroids,” instead of the flat sheets older cell therapies used, mixed with fibroblast-derived material like extracellular vesicles and exosomes (basically tiny signaling packages cells send to their neighbors). Put that on a wound and, according to the company, it doesn’t just sit there. It implants, it migrates across the wound surface, and it keeps sending out repair signals as it goes.
“Spheroids act as living reservoirs that implant on the wound surface, migrate, and proliferate, delivering regenerative signals directly where they are needed,” said Dr Hamid Khoja, chief scientific officer of FibroBiologics. “Our studies demonstrated accelerated wound closure and reduced inflammation, which are critical factors in resolving chronic wounds.”
Why does age matter so much here? Because fibroblasts slow down as people get older. They make less collagen. They’re slower to respond when there’s an injury to fix. Researchers usually lump this under cellular senescence, which is a fancy way of saying the cells are still around; they’ve just stopped doing their job well. Throw diabetes or poor circulation into the mix, both of which become more common later in life, and a cut that would heal in days for a 30-year-old can drag on for months in a 70-year-old. That’s the exact population this patent is written for.
“Wound care is one of the largest unmet needs in medicine, and this patent further solidifies our leadership position in fibroblast-based therapies,” said Pete O’Heeron, founder and CEO of FibroBiologics. “Our preclinical data showed that wounds treated with fibroblast spheroids healed significantly faster than controls, even in diabetic models where healing is notoriously difficult. We believe this technology has the potential to change the standard of care for millions of patients suffering from chronic and nonhealing wounds.”
FibroBiologics says it now holds more than 270 patents, issued or pending, across multiple sclerosis, disc degeneration, psoriasis, orthopedics, cancer and, right there in the company’s own materials, human longevity. So this wound-care patent isn’t really a standalone product story. It’s one working example of a much bigger bet: that fibroblasts, and whatever they’re releasing into the tissue around them, can be used to restart repair processes in parts of the body that have quietly stopped repairing themselves. A foot ulcer is just an easy place to test that, because you can watch it close or not close.
If it holds up, the harder question follows pretty naturally. What else stops healing the way it used to, once the cells doing the healing get old? Cartilage, maybe. Skin elsewhere on the body. FibroBiologics isn’t claiming to have that answer yet; to be clear, this patent is about wounds, not a general anti-aging therapy. But a company sitting on 270 fibroblast-related patents and listing “human longevity” as one of its own stated categories isn’t exactly hiding what it thinks the answer might eventually look like.
